Research Paper Volume 13, Issue 2 pp 2851—2863

A novel methylation signature predicts inferior outcome of patients with PDAC

Kaplan-Meier estimates "progression-free survival" because the diagnosis and progression of the diagnosis are predicted based on the 4-gene signature scores of patients in the training and validation cohort. (A) In the training data set, high-risk patients have poor prognosis and short survival time, PB) The same is true in the validation data set, P=0.00018.

Figure 4. Kaplan-Meier estimates "progression-free survival" because the diagnosis and progression of the diagnosis are predicted based on the 4-gene signature scores of patients in the training and validation cohort. (A) In the training data set, high-risk patients have poor prognosis and short survival time, P<0.001. (B) The same is true in the validation data set, P=0.00018.